
Press Release



ASKA Pharmaceutical Executes Capital Increase to Ha Tay Pharmaceutical Joint Stock Company

TOKYO, January 15, 2024 – ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886, hereinafter "the Company") announced today that ASKA Pharmaceutical Co., Ltd. (Head Office: Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter "ASKA"), a subsidiary of the Company, has executed a capital increase agreement to issue new shares of its equity method affiliate, Ha Tay Pharmaceutical Joint Stock Company (hereinafter "Hataphar"), a Vietnamese pharmaceutical company, and now owns 32.6% of the voting rights of Hataphar's shares.

The impact of this matter on the Company's business performance for JFY2023 has already been factored in.

1. Number of shares acquired, and status of shares held before and after acquisition

(1)	Number	of	shares	held	before	the	18,411,178 shares
	transaction	า:					(holding ratio of voting rights: 24.9%)
(2)	Number of shares acquired:					8,400,000 shares	
(3)	Number	of	shares	held	after	the	26,811,178 shares
transaction:							(holding ratio of voting rights: 32.6%)

2. Overview of Hataphar

Trade name	Ha Tay Pharmaceutical Joint Stock Company			
Business	Manufacturing, import and sale of pharmaceuticals, over-the-			
	counter drugs and nutraceutical products			
Capital	823,417 million VND (4.8 billion JPY*)			
Establishment	1965			
Head Office	Hanoi, Vietnam			
Net sales (FY2022)	1,837,469,503,390 VND (10.71 billion JPY*)			
Operating profit (FY2022)	114,105,294,075 VND (0.67 billion JPY*)			
Net income (FY2022)	98,964,494,295 VND (0.58 billion JPY*)			
Net assets (FY2022)	798,840,658,956 VND (4.66 billion JPY*)			
Total assets (FY2022)	1,469,502,270,857 VND (8.57 billion JPY*)			

*1VND=0.00583JPY

3. Outlook

In order to strengthen the partnership and expand the organization, ASKA will discuss with Hataphar to acquire additional shares from now with a view to further building the relationship. While maintaining Hataphar's independence, the two companies will further strengthen their alliance, aiming for further growth and development of both companies and enhancement of corporate value.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp